GRAND RAPIDS, Mich. — One in eight men will be diagnosed with prostate cancer in their lifetime. Typically, treatment includes hormone medication, and when that fails, chemotherapy.

BAMF Health in Grand Rapids is offering an alternative treatment. It’s called Pluvicto, a radiopharmaceutical therapy targeting prostate cancer cells directly. As of March, patients can now begin this therapy before chemotherapy.

Michael Raymond was a patient benefiting from the FDA approval expansion.

“I already have done my research about theranostics,” said Raymond. “I've heard about the minimal side effects. I want to go that route.”

Two years ago, he was diagnosed with prostate cancer. After medication failed to help, he turned to BAMF Health for Pluvicto.

“It's an injectable treatment that is organic

See Full Page